Business
Alexandria Real Estate Equities, Inc. Celebrates 32 Years of Pioneering Leadership in Life Science Real Estate and Consequential Impact on Advancing Human Health
Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured, and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today celebrates the 32nd anniversary of the company's founding as a garage startup and its creation of life science real estate as a transformative new commercial asset class focused on the critically important life science industry — one that is vital to advancing U.S. h
About this update from Alexandria Real Estate Equities, Inc.
[{"type":"text","content":"PASADENA, Calif., Jan. 5, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured, and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today celebrates the 32nd anniversary of the company's founding as a garage startup and its creation of life science real estate as a transformative new commercial asset class focused on the critically important life science industry — one that is vital to advancing U.S. health, economic resilience, and national security. The significant milestone reaffirms Alexandria's enduring leadership for over three decades at the vanguard of this essential industry, delivering mission-critical infrastructure and creating ecosystems that accelerate life science innovation to address the more than 90% of diseases that still lack effective treatments.","length":927,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Alexandria Real Estate Equities, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Alexandria Real Estate Equities, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":291,"url":"https://media.zenfs.com/en/prnewswire.com/b550f41bc01f59a4dea5032e09f2e6f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nSs9lfxH6jxvUBq0.q447A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b550f41bc01f59a4dea5032e09f2e6f8","width":400,"height":291}},"href":"https://mma.prnewswire.com/media/1930628/Alexandria_Real_Estate_Equities_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""As the cornerstone of U.S. innovation and societal progress, the life science industry is navigating a period of change. Evolving research funding priorities, organizational challenges at the FDA, ongoing private and public capital market issues, drug pricing efforts, and intensifying global competition pose challenges, yet they also reinforce the importance of sustained and robust domestic life science investment to maintain U.S. global leadership. The industry remains central to national security and to the discovery of groundbreaking technologies, therapies, and cures that improve, extend, and save lives. Among the 44 novel therapies approved by the FDA in 2025, 39...